Radius Health, a US-based developer of drug therapies for osteoporosis and women’s health, plans to sell 6.5 million shares at between $8.50 and $10.50 each in its Nasdaq stock exchange flotation. Investment banks UBS and Leerink Swann are co-lead underwriters of Radius’ initial public offering (IPO) that will give the company a $283m market capitalisation…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
